The US Food and Drug Administration said it had found “some credible scientific support for the use of drug in the treatment of chronic pain, disease-related anorexia, and nausea and vomiting.”

“Furthermore, the FDA review did not identify any safety concerns that would indicate that medical use drug poses an unacceptably high security risk,” the proposal states.

President Joe Biden, a Democrat running for re-election in November, has launched a review of the drug’s 2022 dosing schedule, fulfilling a campaign promise that was important to members of his political base on the left.

You might be interested > Violence already costs Mexicans 19.8% of GDP

The drug is currently classified in the same classification as heroin and LSD. You would move to a group containing ketamine and Tylenol with codeine.

Reclassification drug represents the first step toward bridging the gap between state and federal cannabis laws. The drug is legal in nearly 40 states in some form.

While reclassifying the drug does not make it legal, it will open the door to greater research and medical use, potentially help reduce criminal penalties and increase investment in the cannabis sector.

If classification drug If this were relaxed at the federal level, cannabis companies could see significant benefits, such as the ability to list on major stock exchanges and more generous tax deductions. (Reuters).